{"classes":[{"categories":[{"measurements":[{"comment":"The geometric mean and geometric coefficient of variation were not estimable as majority of the values were lower than reportable.","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"401"}],"units":"Participants"}],"title":"Pre-infusion on Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"57.4","value":"4.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"397"}],"units":"Participants"}],"title":"15-30 minutes post-infusion on Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.2","value":"3.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"387"}],"units":"Participants"}],"title":"2 hours post-infusion on Cycle 1"},{"categories":[{"measurements":[{"comment":"The geometric coefficient of variation was not estimable as majority of the values were lower than reportable or zero.","groupId":"OG000","spread":"NA","value":"0.372"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"361"}],"units":"Participants"}],"title":"Pre-infusion on Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.8","value":"4.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"}],"units":"Participants"}],"title":"15-30 minutes post-infusion on Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"41.0","value":"3.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"347"}],"units":"Participants"}],"title":"2 hours post-infusion on Cycle 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"417"}],"units":"Participants"}],"description":"Concentration of DM1 in plasma was measured through the samples obtained from participants randomized to the trastuzumab emtansine arm. DM1 is an ant-microtubule agent derived from maytansine. In transtuzumab entansine, DM1 is linked to the antibody transtuzumab thus helping the drug to specifically target the HER 2- positive cancer cells.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received trastuzumab emtansine, 3.6 mg/kg, IV, Q3W for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.","id":"OG000","title":"Trastuzumab Emtansine"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK-evaluable population included all participants who received atleast 1 dose of trastuzumab emtansine and had at least one evaluable post dose PK sample. Overall number analyzed is the number of participants with data available for analysis. Number analyzed per timepoint are unique number of participants out of all the assessed participants with data available for analysis at the specified timepoint. Different participants may have contributed data for each timepoint.","reportingStatus":"POSTED","timeFrame":"Pre-infusion, 15-30 minutes and 2 hour post-infusion on Cycles 1 and 4 (1 cycle = 21 days)","title":"Plasma Concentrations of Deacetyl Mercapto 1-Oxopropyl Maytansine (DM1)","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/mL)"}